Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

Blas-García A, Polo M, Alegre F, Funes HA, Martínez E, Apostolova N, Esplugues JV.

J Antimicrob Chemother. 2014 Nov;69(11):2995-3000. doi: 10.1093/jac/dku262.

PMID:
25011651
2.

ER stress in human hepatic cells treated with Efavirenz: mitochondria again.

Apostolova N, Gomez-Sucerquia LJ, Alegre F, Funes HA, Victor VM, Barrachina MD, Blas-Garcia A, Esplugues JV.

J Hepatol. 2013 Oct;59(4):780-9. doi: 10.1016/j.jhep.2013.06.005.

PMID:
23792026
3.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group..

Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.

PMID:
21763935
4.

Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.

[No authors listed]

Prescrire Int. 2012 Nov;21(132):262-5.

PMID:
23210255
5.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group..

Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.

PMID:
21763936
6.

Mitochondrial (dys)function - a factor underlying the variability of efavirenz-induced hepatotoxicity?

Polo M, Alegre F, Funes HA, Blas-Garcia A, Victor VM, Esplugues JV, Apostolova N.

Br J Pharmacol. 2015 Apr;172(7):1713-27. doi: 10.1111/bph.13018.

7.

Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.

Molina JM, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M; ECHO and THRIVE Study Groups..

HIV Med. 2014 Jan;15(1):57-62. doi: 10.1111/hiv.12071.

8.

Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells.

Weiß M, Kost B, Renner-Müller I, Wolf E, Mylonas I, Brüning A.

Cardiovasc Toxicol. 2016 Jan;16(1):90-9. doi: 10.1007/s12012-015-9314-2.

PMID:
25666561
9.

Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz.

Funes HA, Apostolova N, Alegre F, Blas-Garcia A, Alvarez A, Marti-Cabrera M, Esplugues JV.

J Infect Dis. 2014 Nov 1;210(9):1385-95. doi: 10.1093/infdis/jiu273.

PMID:
24813473
10.

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.

Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M; ECHO Study Group.; THRIVE Study Group..

AIDS. 2013 Mar 27;27(6):889-97. doi: 10.1097/QAD.0b013e32835e1554.

PMID:
23276806
11.

Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz.

Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV, Apostolova N.

Antiviral Res. 2012 Jun;94(3):232-41. doi: 10.1016/j.antiviral.2012.04.003.

PMID:
22554935
13.

Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors.

Sharma D, Lau AJ, Sherman MA, Chang TK.

Biochem Pharmacol. 2013 Jun 1;85(11):1700-11. doi: 10.1016/j.bcp.2013.04.002.

PMID:
23583259
14.

Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K; ECHO and THRIVE study groups..

HIV Med. 2013 Aug;14(7):391-400. doi: 10.1111/hiv.12012.

15.

Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.

Dailly E, Allavena C, Bouquié R, Deslandes G, Raffi F, Jolliet P.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):42-6. doi: 10.1089/AID.2012.0188.

PMID:
23148588
16.

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):39-46. doi: 10.1097/QAI.0b013e31823df4da.

PMID:
22067667
17.

[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].

Domingo P, Ribera E.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:20-9. doi: 10.1016/S0213-005X(13)70139-3. Review. Spanish.

PMID:
24252530
18.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups..

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772
19.

Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.

Díaz-Delfín J, Domingo P, Mateo MG, Gutierrez Mdel M, Domingo JC, Giralt M, Villarroya F.

Antimicrob Agents Chemother. 2012 Jun;56(6):3369-75. doi: 10.1128/AAC.00104-12.

20.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091

Supplemental Content

Support Center